Track topics on Twitter Track topics that are important to you
DELRAY BEACH, Fla., Aug. 10, 2015 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced today that it has been selected to present a poster and exhibit at the 2015 Military Health System Research Symposium (MHSRS) Conference on August 17-20, 2015, at the Marriott Harbor Beach Resort in Fort Lauderdale, FL. PositiveID will showcase its biological detection and diagnostics products, primarily its Firefly Dx, during the conference in Booth #50.
The Company’s poster, “Firefly Dx; Point-Of-Care Infectious Disease Detection and Diagnostics,” describes the development of the handheld, point-of-care (POC) diagnostics system for rapid identification of naturally occurring infectious diseases within 20 minutes. The Firefly Dx system uses assay specific, disposable cartridges in conjunction with a handheld device, and is designed to be a cost-effective diagnostic tool capable of easy and rapid onsite analysis against multiple user-defined pathogenic targets of interest.
Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
The MHSRS is the Department of Defense’s premier scientific meeting. It is a venue for communicating and discussing new scientific knowledge resulting from military-unique research and development. It is the only military or civilian meeting that focuses specifically on the unique medical needs of the Warfighter.
The MHSRS provides a scholarly forum for the planning and development of future studies aimed at optimizing care for members of the Uniformed Services in operational settings. Held in a collaborative, joint setting, it enables military medical care providers with deployment experience to exchange information with Department of Defense and academic scientists, international partners, and industry on research and related health care initiatives falling under the topic areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, and Military Infectious Disease. Its goal is to maximize research synergy among all of the branches of military service, while acknowledging the need for service-specific medical capabilities.
The MHSRS is an annual event that is sponsored by the Assistant Secretary of Defense for Health Affairs.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America’s homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including the likelihood that Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment, highly trained personnel, and can take hours or even days to provide results; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the bio-threat detection and rapid medical testing sectors; the Company’s ability to complete the development of its Firefly Dx system; the Company’s ability to win government contracts; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 30, 2015, and 10-Qs filed on May 15, 2015, November 17, 2014, and August 14, 2014, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact: PositiveID Corporation Allison Tomek (561) 805-8044 firstname.lastname@example.org Investor Relations Circadian Group (647) 930-1037NEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...